糖尿病足潰瘍治療藥物市場:開發平台分析與市場預測

>糖尿病足潰瘍(DFU)治療藥市場預計將從2011年的15億3,000萬美元緩慢擴大，到2019年達到19億7,000萬美元的規模。該市場糖尿病足潰瘍(DFU)分為治療藥與創傷治療藥兩大領域，一般預測到2019年，各自將以CAGR1.0%、23.4%擴大。前者由於現行藥的副作用，及抗生素抗藥性的增加等問題，後者則是主力藥在2008年必須標上黑框警語，因此雙方在開創新藥上都有極高的需求。

本報告提供全球糖尿病足潰瘍治療藥物市場相關的開發平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，再加入未來市場競爭、企業簡介等資料，為您概述為以下內容。

1 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 糖尿病足潰瘍治療藥物 - 簡介

• 2.1 概要
• 2.1.1 糖尿病足潰瘍 分類系統
• 2.2 免疫學
• 2.2.1 到現在為止的糖尿病足潰瘍
• 2.2.2 今後的糖尿病足潰瘍
• 2.3 預後診斷
• 2.4 病因
• 2.5 症狀
• 2.6 診斷

2.6.1 病歷

• 2.6.2 神經檢驗
• 2.6.3 血管檢驗
• 2.6.4 肌肉骨骼系統檢驗
• 2.6.5 創傷的評估
• 2.6.6 臨床檢驗及影像診斷
• 2.7 病理學
• 2.8 治療及管理模式
• 2.8.1 感染疾病的管理
• 2.8.2 機器負擔的減輕
• 2.8.3 創傷護理/壞死組織消除策略
• 2.8.4 血糖管理
• 2.8.5 患者教育
• 2.9 問診途徑
• 2.10 GlobalData 開發平台報告指南

3 糖尿病足潰瘍治療藥物 - 市場特性

• 3.1 糖尿病足潰瘍 治療藥物市場規模 - 全球
• 3.2 糖尿病足潰瘍 治療藥物市場預測 - 全球
• 3.3 糖尿病足潰瘍 治療藥物市場規模 - 美國
• 3.4 糖尿病足潰瘍 治療藥物市場預測 - 美國
• 3.5 糖尿病足潰瘍 治療藥物市場規模 - 法國
• 3.6 糖尿病足潰瘍 治療藥物市場預測 - 法國
• 3.7 糖尿病足潰瘍 治療藥物市場規模 - 德國
• 3.8 糖尿病足潰瘍 治療藥物市場預測 - 德國
• 3.9 糖尿病足潰瘍 治療藥物市場規模 - 義大利
• 3.10 糖尿病足潰瘍 治療藥物市場預測 - 義大利
• 3.11 糖尿病足潰瘍 治療藥物市場規模 - 西班牙
• 3.12 糖尿病足潰瘍 治療藥物市場預測 - 西班牙
• 3.13 糖尿病足潰瘍 治療藥物市場規模 - 英國
• 3.14 糖尿病足潰瘍 治療藥物市場預測 - 英國
• 3.15 糖尿病足潰瘍 治療藥物市場規模 - 日本
• 3.16 糖尿病足潰瘍 治療藥物市場預測 - 日本
• 3.17 促進成長要素及障礙;糖尿病足潰瘍 治療藥物市場
• 3.17.1 促進成長要素
• 3.17.2 障礙
• 3.18 市場機會及未飽和需求
• 3.19 要點

4 糖尿病足潰瘍治療藥物 - 競爭評估

• 4.1 概要
• 4.2 策略性競爭評估
• 4.3 主要上市產品簡介
• 4.4 抗感染藥
• 4.4.1 Invanz (ertapenem)
• 4.4.2 Zosyn (piperacillin/tazobactam)
• 4.4.3 Zyvox (linezolid)
• 4.5 傷口護理產品
• 4.5.1 Regranex (becaplermin)
• 4.6 要點

5 糖尿病足潰瘍治療藥物 - 開發平台評估

• 5.1 概要
• 5.2 策略性開發平台評估
• 5.3 糖尿病足潰瘍治療藥物 - 開發平台分析, 各開發階段
• 5.3.1 第三階段開發平台
• 5.3.2 第二階段開發平台
• 5.3.3 第一階段開發平台
• 5.3.4 前臨床及藥物發明開發平台
• 5.4 糖尿病足潰瘍治療藥物 - 各作用機制平台
• 5.5 技術趨勢的分析架構
• 5.6 潛力治療藥物簡介
• 5.6.1 CVBT-141B (FGF-1)
• 5.6.2 Fragmin (dalteparin sodium)
• 5.6.3 Trafermin
• 5.6.4 Heberprot-P
• 5.6.5 HO/03/03
• 5.6.6 CureXcell
• 5.7 要點

6 糖尿病足潰瘍治療藥物 - 臨床實驗藍圖

• 6.1 各區各國
• 6.2 各臨床開發階段
• 6.3 各臨床實驗狀態
• 6.4 各贊助商
• 6.5 主要參與臨床實驗企業

7 糖尿病足潰瘍治療藥物 - 策略性評估

• 7.1 影響未來市場的主要事件
• 7.2 未來市場競爭模式

8 糖尿病足潰瘍治療藥物 - 有未來潛力的企業

• 8.1 簡介
• 8.2 企業簡介
• 8.2.1 Pfizer Inc.
• 8.2.2 Cardiovascular Biotherapeutics, Inc.
• 8.2.3 HealOr Ltd.
• 8.2.4 MacroCure Ltd.
• 8.2.5 成行向(到)開發平台的其他的企業

9 糖尿病足潰瘍治療藥物 - 授權合約及合作交易

10 附錄

• 10.1 市場定義
• 10.2 簡稱
• 10.3 參考文獻
• 10.4 為本調查合作領受了的醫生及專家
• 10.5 調查方法
• 10.5.1 調查範圍
• 10.5.2 二級研究
• 10.5.3 預測
• 10.5.4 主要研究
• 10.5.5 專門委員會驗證
• 10.6 諮詢方式
• 10.7 免責聲明

表格一覽

圖表一覽

Abstract

Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Foot Ulcers Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Diabetic Foot Ulcers Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Foot Ulcers Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Diabetic Foot Ulcers Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Foot Ulcers Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Diabetic Foot Ulcers Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Diabetic Foot Ulcers Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global Diabetic Foot Ulcers Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

• 1.1 List of Tables 5
• 1.2 List of Figures 6

2 Diabetic Foot Ulcer Therapeutics - Introduction 7

• 2.1 Overview 7
• 2.1.1 Diabetic Foot Ulcer Classification Systems 7
• 2.2 Epidemiology 10
• 2.2.1 Historic Epidemiology (2006-2011) 10
• 2.2.2 Forecast Epidemiology (2011-2019) 10
• 2.3 Prognosis 11
• 2.4 Etiology 11
• 2.5 Symptoms 12
• 2.6 Diagnosis 12

2.6.1 History 12

• 2.6.2 Neurologic Examination 12
• 2.6.3 Vascular Examination 13
• 2.6.4 Musculoskeletal Examination 13
• 2.6.5 Wound Evaluation 13
• 2.6.6 Laboratory Testing and Imaging Studies 13
• 2.7 Pathophysiology 14
• 2.8 Treatment and Management Pattern 15
• 2.8.1 Infection Control 15
• 2.8.2 Mechanical Load Relief 16
• 2.8.3 Wound Care/Debridement 16
• 2.8.4 Blood Glucose Control 16
• 2.8.5 Patient Education 17
• 2.9 Referral Pathway 17
• 2.10 GlobalData Pipeline Report Guidance 18

3 Diabetic Foot Ulcer Therapeutics - Market Characterization 19

• 3.1 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Global 19
• 3.2 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Global 21
• 3.3 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The US 23
• 3.4 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The US 25
• 3.5 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - France 27
• 3.6 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - France 29
• 3.7 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Germany 31
• 3.8 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Germany 33
• 3.9 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Italy 35
• 3.10 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Italy 37
• 3.11 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Spain 39
• 3.12 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Spain 41
• 3.13 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The UK 43
• 3.14 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The UK 45
• 3.15 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Japan 47
• 3.16 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Japan 49
• 3.17 Drivers and Barriers for the Diabetic Foot Ulcer Therapeutics Market 51
• 3.17.1 Drivers of the Diabetic Foot Ulcer Therapeutics Market 51
• 3.17.2 Barriers for the Diabetic Foot Ulcer Therapeutics Market 52
• 3.18 Opportunity and Unmet Need 53
• 3.19 Key Takeaway 54

4 Diabetic Foot Ulcer Therapeutics - Competitive Assessment 55

• 4.1 Overview 55
• 4.2 Strategic Competitor Assessment 55
• 4.3 Product Profiles for the Major Marketed Products in the Diabetic Foot Ulcer Therapeutics Market 57
• 4.4 Anti-infectives 57
• 4.4.1 Invanz (ertapenem) 57
• 4.4.2 Zosyn (piperacillin/tazobactam) 58
• 4.4.3 Zyvox (linezolid) 59
• 4.5 Wound-healing Products 60
• 4.5.1 Regranex (becaplermin) 60
• 4.6 Key Takeaway 61

5 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment 62

• 5.1 Overview 62
• 5.2 Strategic Pipeline Assessment 62
• 5.3 Diabetic Foot Ulcer Therapeutics - Pipeline Analysis by Phase of Development 62
• 5.3.1 Diabetic Foot Ulcer Therapeutics - Phase III Pipeline 62
• 5.3.2 Diabetic Foot Ulcer Therapeutics - Phase II Pipeline 63
• 5.3.3 Diabetic Foot Ulcer Therapeutics - Phase I Pipeline 64
• 5.3.4 Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline 64
• 5.4 Diabetic Foot Ulcer Therapeutics - Pipeline by Mechanism of Action 65
• 5.5 Technology Trends Analytical Framework 67
• 5.6 Profiles of Promising Drugs 68
• 5.6.1 CVBT-141B (FGF-1) 68
• 5.6.2 Fragmin (dalteparin sodium) 69
• 5.6.3 Trafermin 70
• 5.6.4 Heberprot-P 70
• 5.6.5 HO/03/03 71
• 5.6.6 CureXcell 71
• 5.7 Key Takeaway 71

6 Diabetic Foot Ulcer Therapeutics - Clinical Trial Mapping 72

• 6.1 Clinical Trials by Region and Country 72
• 6.2 Clinical Trials by Phase of Clinical Development 73
• 6.3 Clinical Trials by Trial Status 74
• 6.4 Clinical Trials by Sponsors 75
• 6.5 Top Companies Participating in Diabetic Foot Ulcer Therapeutics Clinical Trials 77

7 Diabetic Foot Ulcer Therapeutics - Strategic Assessment 78

• 7.1 Key Events Impacting the Future Market 78
• 7.2 Future Market Competition Scenario 79

8 Diabetic Foot Ulcer Therapeutics - Future Players 81

• 8.1 Introduction 81
• 8.2 Company Profiles 81
• 8.2.1 Pfizer Inc. 81
• 8.2.2 Cardiovascular Biotherapeutics, Inc. 83
• 8.2.3 HealOr Ltd. 83
• 8.2.4 MacroCure Ltd. 84
• 8.2.5 Other Companies in the Pipeline 84

9 Diabetic Foot Ulcer Therapeutics - Licensing and Partnership Deals 88

10 Diabetic Foot Ulcer Therapeutics - Appendix 89

• 10.1 Market Definitions 89
• 10.2 Abbreviations 89
• 10.3 Bibliography 90
• 10.4 Physicians and Specialists Included in this Study 92
• 10.5 Research Methodology 92
• 10.5.1 Coverage 92
• 10.5.2 Secondary Research 92
• 10.5.3 Forecasting 93
• 10.5.4 Primary Research 95
• 10.5.5 Expert Panel Validation 96
• 10.6 Contact Us 96
• 10.7 Disclaimer 96

List of Tables

1.1 List of Tables

• Table 1: Diabetic Foot Ulcer - Wagner-Meggitt Classification 7
• Table 2: The University of Texas - Diabetic Wound Classification System 8
• Table 3: Diabetic Foot Ulcer, Global, Prevalence Population, 2006-2011 10
• Table 4: Diabetic Foot Ulcer, Global, Prevalence Population, 2011-2019 10
• Table 5: Diabetic Foot Ulcer - Risk Factors 11
• Table 6: Diabetic Foot Infections - Empirical Antibiotic Regimens 15
• Table 7: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 20
• Table 8: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20
• Table 9: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21
• Table 10: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22
• Table 11: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23
• Table 12: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24
• Table 13: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25
• Table 14: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26
• Table 15: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27
• Table 16: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28
• Table 17: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29
• Table 18: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30
• Table 19: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31
• Table 20: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
• Table 21: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33
• Table 22: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34
• Table 23: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
• Table 24: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36
• Table 25: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37
• Table 26: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38
• Table 27: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39
• Table 28: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40
• Table 29: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41
• Table 30: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
• Table 31: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
• Table 32: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44
• Table 33: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45
• Table 34: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
• Table 35: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
• Table 36: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48
• Table 37: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49
• Table 38: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50
• Table 39: Diabetic Foot Ulcer Therapeutics - Phase III Pipeline, 2012 62
• Table 40: Diabetic Foot Ulcer Therapeutics - Phase II Pipeline, 2012 63
• Table 41: Diabetic Foot Ulcer Therapeutics - Phase I Pipeline, 2012 64
• Table 42: Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline, 2012 64
• Table 43: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials, 2012 72
• Table 44: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase, 2012 73
• Table 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development, 2012 74
• Table 46: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors, 2012 75
• Table 47: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors, 2012 76
• Table 48: Diabetic Foot Ulcer Therapeutics, Global, Top Ten Companies by Phase, 2012 77
• Table 49: Pfizer, Inc. - Diabetic Foot Ulcer Pipeline Products, 2012 82
• Table 50: Cardiovascular Biotherapeutics, Inc. - DFU Pipeline Products, 2012 83
• Table 51: HealOr Ltd. - DFU Pipeline Products, 2012 83
• Table 52: MacroCure Ltd. - DFU Pipeline Products, 2012 84
• Table 53: Diabetic Foot Ulcer Therapeutics - Other Companies in the Pipeline, 2012 84
• Table 54: Diabetic Foot Ulcer Therapeutics, Licensing and Partnership Deals, 2012 88

List of Figures

1.2 List of Figures

• Figure 1: The University of Texas - Diabetic Wound Classification System 9
• Figure 2: Diabetic Foot Ulcer - Pathophysiology 14
• Figure 3: Diabetic Foot Infections - Antibiotic Use According to Clinical Severity 16
• Figure 4: Diabetic Foot Ulcer - Referral Pathway 17
• Figure 5: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 19
• Figure 6: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20
• Figure 7: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21
• Figure 8: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22
• Figure 9: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23
• Figure 10: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24
• Figure 11: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25
• Figure 12: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26
• Figure 13: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27
• Figure 14: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28
• Figure 15: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29
• Figure 16: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30
• Figure 17: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31
• Figure 18: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
• Figure 19: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33
• Figure 20: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34
• Figure 21: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
• Figure 22: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36
• Figure 23: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37
• Figure 24: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38
• Figure 25: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39
• Figure 26: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40
• Figure 27: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41
• Figure 28: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42
• Figure 29: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43
• Figure 30: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44
• Figure 31: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45
• Figure 32: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46
• Figure 33: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47
• Figure 34: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48
• Figure 35: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49
• Figure 36: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50
• Figure 37: Diabetic Foot Ulcer Therapeutics Market, Drivers and Barriers, 2012 52
• Figure 38: Opportunity and Unmet Need in Diabetic Foot Infection Therapeutics Market, 2012 53
• Figure 39: Opportunity and Unmet Need in the Diabetic Foot Ulcer Wound-healing Therapeutics Market, 2012 54
• Figure 40: Strategic Competitor Assessment of the Marketed Products in Diabetic Foot Ulcer Therapeutics, 2012 56
• Figure 41: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012 65
• Figure 42: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Phase of Development (%), 2012 66
• Figure 43: Technology Trends Analytics Framework, 2012 67
• Figure 44: Technology Trends Analytics Framework - Description, 2012 68
• Figure 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Country, 2012 72
• Figure 46: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase (%), 2012 73
• Figure 47: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development (%), 2012 74
• Figure 48: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors (%), 2012 75
• Figure 49: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors (%), 2012 76
• Figure 50: Diabetic Foot Ulcer Therapeutics, Global, Top Companies by Phase, 2012 77
• Figure 51: Diabetic Foot Ulcer Therapeutics Market, Impact Analysis, 2012 78
• Figure 52: Implications for Future Market Competition in the Diabetic Foot Ulcer Therapeutics Market, 2012 79
• Figure 53: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Company, 2012 81
• Figure 54: GlobalData Market Size Estimation 93
• Figure 55: GlobalData Market Forecasting Model 95

全球糖尿病足潰瘍治療藥物市場2019年預計將達到19億7000萬美元的規模